---
figid: PMC6527283__koni-08-07-1596004-g002
figlink: /pmc/articles/PMC6527283/figure/F0002/
number: Figure 2
caption: The mechanisms of macrophage-mediated resistance to chemotherapy.The pathways
  responsible for the tumor-promoting function of TAMs after chemotherapy and chemoresistance
  include the increased recruitment of immunosuppressive TAMs, the pro-tumor polarization,
  the reduced T-cell cytotoxic response, the activation of anti-apoptotic programs
  in malignant cells. a. TAMs which contribute to tumor resistance to doxorubicin
  have high expression of CD68, CD206, CD163, PD-L1, but low expression of CD80 and
  CD86. Moreover, TAMs release immunosuppressive cytokines (IL10 and TGFβ), factors
  which promote invasion (MMP9, MMP13), pro-angiogenic factor VEGF which cause revascularization.
  Increased expression of PDL1 in TAMs limits tumor response to chemotherapy by suppression
  the antitumor functions of cytotoxic T cells resulting in tumor cell survival and
  proliferation, and chemoresistance. b. TAM-mediated resistance to carboplatin is
  associated with STAT3 signaling and macrophage-produced IL6 promoting tumor cell
  growth. TAM exosomes are involved in cisplatin resistance via the activation of
  the PI3K/AKT signaling pathway in tumor cells. c. Chemoresistance to gemcitabine
  is mediated by decreasing the activation of caspase-3 and reducing the apoptosis
  in tumor cells. d. Cathepsin proteases (cathepsin B and S) secreted by TAMs mediate
  chemoprotection through NF-κβ activation, or indirectly through IL-6 expression
  and STAT3 activation. There are unknown mechanisms of chemotherapy influence on
  macrophages.
pmcid: PMC6527283
papertitle: Interaction of tumor-associated macrophages and cancer chemotherapy.
reftext: Irina Larionova, et al. Oncoimmunology. 2019;8(7):1596004.
pmc_ranked_result_index: '39092'
pathway_score: 0.9430269
filename: koni-08-07-1596004-g002.jpg
figtitle: Interaction of tumor-associated macrophages and cancer chemotherapy.
year: '2019'
organisms: Homo sapiens
ndex: 5800343e-ded5-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6527283__koni-08-07-1596004-g002.html
  '@type': Dataset
  description: The mechanisms of macrophage-mediated resistance to chemotherapy.The
    pathways responsible for the tumor-promoting function of TAMs after chemotherapy
    and chemoresistance include the increased recruitment of immunosuppressive TAMs,
    the pro-tumor polarization, the reduced T-cell cytotoxic response, the activation
    of anti-apoptotic programs in malignant cells. a. TAMs which contribute to tumor
    resistance to doxorubicin have high expression of CD68, CD206, CD163, PD-L1, but
    low expression of CD80 and CD86. Moreover, TAMs release immunosuppressive cytokines
    (IL10 and TGFβ), factors which promote invasion (MMP9, MMP13), pro-angiogenic
    factor VEGF which cause revascularization. Increased expression of PDL1 in TAMs
    limits tumor response to chemotherapy by suppression the antitumor functions of
    cytotoxic T cells resulting in tumor cell survival and proliferation, and chemoresistance.
    b. TAM-mediated resistance to carboplatin is associated with STAT3 signaling and
    macrophage-produced IL6 promoting tumor cell growth. TAM exosomes are involved
    in cisplatin resistance via the activation of the PI3K/AKT signaling pathway in
    tumor cells. c. Chemoresistance to gemcitabine is mediated by decreasing the activation
    of caspase-3 and reducing the apoptosis in tumor cells. d. Cathepsin proteases
    (cathepsin B and S) secreted by TAMs mediate chemoprotection through NF-κβ activation,
    or indirectly through IL-6 expression and STAT3 activation. There are unknown
    mechanisms of chemotherapy influence on macrophages.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFD
  - VEGFB
  - CASP14
  - PGF
  - CASP2
  - CASP12
  - CASP4
  - CASP1
  - PDCD1
  - CASP3
  - VEGFA
  - VEGFC
  - PIK3CD
  - AKT2
  - AKT3
  - PIK3CG
  - PIK3R6
  - PIK3R5
  - PIK3R4
  - PIK3CA
  - PIK3CB
  - AKT1
  - STAT3
  - CD86
  - PIK3R3
  - CASP8
  - CASP9
  - CASP10
  - CASP6
  - CASP7
  - TP53
  - CASP5
  - Doxorubicin
  - Cisplatin
  - Carboplatin
  - Gemcitabine
  - Paclitaxel
  - Mo
  - PGE21
  - Death
  - tumor
genes:
- word: VEGF!
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF!
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP14
  entrez: '23581'
- word: VEGF!
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP2
  entrez: '835'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP12
  entrez: '100506742'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP4
  entrez: '837'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP1
  entrez: '834'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP3
  entrez: '836'
- word: VEGF!
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF!
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: P13K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: P13K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: P13K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: P13K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: P13K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: P13K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: P13K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: P13K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: P13K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: P13K/AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: (STAT3
  symbol: STAT3
  source: hgnc_symbol
  hgnc_symbol: STAT3
  entrez: '6774'
- word: CD86
  symbol: CD86
  source: hgnc_symbol
  hgnc_symbol: CD86
  entrez: '942'
- word: P13K/AKT
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP8
  entrez: '841'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP9
  entrez: '842'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP10
  entrez: '843'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP6
  entrez: '839'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP7
  entrez: '840'
- word: P53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP5
  entrez: '838'
chemicals:
- word: Doxorubicin
  source: MESH
  identifier: D004317
- word: Cisplatin
  source: MESH
  identifier: D002945
- word: Carboplatin
  source: MESH
  identifier: D016190
- word: Gemcitabine
  source: MESH
  identifier: C056507
- word: Paclitaxel
  source: MESH
  identifier: D017239
- word: Mo
  source: MESH
  identifier: D008982
- word: PGE21
  source: MESH
  identifier: D011458
diseases:
- word: Death
  source: MESH
  identifier: D003643
- word: tumor
  source: MESH
  identifier: D009369
---
